Monitor for the next quarterly report or pipeline update — the CFO change is routine and does not alter the company's operational trajectory. The internal CAO replacement suggests a smooth transition.
Price Chart
Executive Summary
Kalaris Therapeutics appointed Liisa Bayko as CFO and Treasurer, effective July 20, 2026, with a $475K base salary, 40% target bonus, and 220,000-share option grant. Separately, CAO Brett Hagen resigned effective July 27, 2026, and Corporate Controller Amy Vandekop was named interim principal accounting officer. These are routine officer changes without material financial impact.
Key Facts
- Liisa Bayko appointed CFO and Treasurer effective July 20, 2026
- Bayko's base salary: $475,000 per year
- Bayko eligible for annual bonus up to 40% of base salary (Target Bonus)
- Bayko granted option to purchase 220,000 shares of common stock, vesting over 4 years
- Brett Hagen resigned as SVP, Finance and Chief Accounting Officer effective July 27, 2026
- Amy Vandekop designated interim principal accounting officer effective July 27, 2026
Financial Impact
No financial impact from these officer changes; compensation terms are standard for a biotech CFO role.
Risk Factors
- Resignation of CAO could indicate internal finance function instability, though internal replacement mitigates risk
- No material financial data disclosed; stock impact likely minimal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-308382 |
| Document: d125092d8k.htm | 0001193125-26-308382 |
| Document: 0001193125-26-308382-index-headers.html | 0001193125-26-308382 |
| Document: 0001193125-26-308382-index.html | 0001193125-26-308382 |
| Document: 0001193125-26-308382.txt | 0001193125-26-308382 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13G | $1.80 | awaiting T+60 | — | $1.84 (+1.94%) |
Aug 11, 2026 11w ago | 8-K | $3.97 | awaiting T+60 | — | $1.84 (−53.78%) |
Aug 11, 2026 11w ago | Press Release | $3.97 | awaiting T+60 | — | $1.84 (−53.78%) |
Aug 3, 2026 12w ago | 3 | $4.32 | awaiting T+60 | — | $1.84 (−57.52%) |
Jul 20, 2026 14w ago | 8-K | $4.00 $2.23 | ▼ −44.25% | ▼ −49.09% | $1.84 (−54.12%) |
Jul 17, 2026 14w ago | 8-K | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.84 (−58.11%) |
Jul 17, 2026 14w ago | Press Release | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.84 (−58.11%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.36 $3.90 | ▼ −10.55% | ▼ −14.95% | $1.84 (−57.91%) |
May 12, 2026 24w ago | 8-K | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.84 (−61.69%) |
May 12, 2026 24w ago | Press Release | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.84 (−61.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers